

**Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.**



The Journal of Medical Entomology and Parasitology is one of the series issued quarterly by the Egyptian Academic Journal of Biological Sciences. It is an important specialist journal covering the latest advances in that subject.

It publishes original research and review papers on all aspects of basic and applied medical entomology, parasitology and host-parasite relationships, including the latest discoveries in parasite biochemistry, molecular biology, genetics, ecology and epidemiology in the content of the biological, medical entomology and veterinary sciences.

In addition to that, the journal promotes research on the impact of living organisms on their environment with emphasis on subjects such a resource, depletion, pollution, biodiversity, ecosystem.....etc.

www.eajbs.eg.net



Parasitological and Biochemicals studies on The Impact of Chitosan Nanoparticles on the course of Murine, *Schistosomiasis mansoni*

Abdo N.A.¹, Ghobashy M.A.F.¹, Mahmoud S.S.², Ismail O. A.³, Hassan E.A.¹

1-Zoology Department -Faculty of Science-Suez Canal University

2- Parasitology- Theodore Bilharz Research Institute

3- Faculty of Medicine- Suez Canal University

E-mail: noorhan.ahmed82@yahoo.com

ARTICLE INFO

Article History

Received:4/11/2019

Accepted:26/12/2019

Keywords:

Lantana camera;

Mentha piperita

L.; *Eucalyptis*

grandis; *Aedes*

aegypti; *Culex*

quinquefasciatus;

larvicide;

repellency.

ABSTRACT

Schistosomiasis is a worldwide disease and affects more than 200 million individuals around the world but its treatment depending only on a single orally drug, praziquantel.

Since praziquantel was developed in 1970, it has replaced other anti-schistosomal drugs to become only drug of choice for treatment of human schistosomiasis due to, high efficacy, excellent tolerability, few and transient side effects, simple administration and competitive cost, but many factors can affect on its efficacy (internal such as; ph, enzymes or external such as; temperature, humidity).

So the development of a vaccine would be essential for the control of schistosomiasis, which is recognized as the most important human helminths infection in terms of morbidity and mortality. A new approach of oral vaccination with chitosan nanoparticles appears interesting because of their great stability and the ease of target accessibility, besides chitosan immunostimulatory properties.

This work aimed to study the effect of chitosan loaded with praziquantel nanoparticles as a delivery drug system on parasitological parameters such as (worm burden, oogram, in addition to the effect of the drug on biochemical parameters.

The results showed that chitosan loaded with PZQ as nanoparticles have a great effect on worm burden reduction reached 97.12% and worm's stages reached 99.6% dead ova. Also it improved host biochemical parameters performance. The present study suggests that drug delivery system represented in chitosan has more advantages rather than taking the treatment (PZQ) orally alone.

INTRODUCTION

Schistosomiasis affected about 250 million people worldwide and an estimated 4,400 to 200,000 people die from it each year (Thétiot-Laurent, *et al.*, 2013). The disease is most commonly found in Africa, Asia, and South America but Schistosomiasis is listed as a neglected tropical disease (Lammie *et al.*, 2006; Steinmann *et al.*, 2006 and Hotez *et al.*, 2009). Praziquantel is a drug available for the treatment of schistosomiasis, because of praziquantel lower cost per treatment, and for its safety (Cioli, 2000 and Danso-Appiah *et al.*, 2013). A considerable portion of a drug is distributed nonspecifically over healthy tissues and organs in the body, thus leading to severe side effects.

So, it is important to use a drug delivery to maintain the drug encapsulated from many external and internal conditions such as gut (Ph. or enzymes) (Bell, 2001). Recently a nanoparticle as a delivery system to load PZQ to its target tissue are widely used (Kwon *et al.*, 2005 and Reddy *et al.*, 2007). Chitosan is a naturally occurring and abundantly available biocompatible polysaccharide (Shrestha *et al.*, 2014). Collectively, as an attractive carrier and adjuvant, Chitosan has been used extensively in vaccine applications (Islam and Ferro, 2016).

MATERIALS AND METHODS

Study Materials:

1) Animals:

Eighty-four male Swiss albino pathogen-free mice, strain CD1, weighing (20-22 g) at the beginning of the experiment and had similar age (6-8 weeks) were used. The animals were provided by The Schistosoma Biology Supply Program (SBSP) of the Theodor Bilharz Research Institute (TBRI), Giza, and Egypt

2) Parasites:

-*Schistosoma mansoni* cercariae were obtained from laboratory-bred infected *Biomphalaria alexandrina* snails in SBSP at TBRI, Giza, Egypt.

3) Drugs and Dosage:

A. Praziquantel (PZQ) 500 mg/kg tablets (Praziquantel-Sedico Pharmaceutical Co. 6th of October City, Egypt), was orally administered at a dose of 500 mg/kg body weight for two consecutive days (Piper *et al.*, 1990). It was freshly prepared before use as a 2% suspension in Cremophor- E1 (Sigma Chemical Co., St. Louis, MO, USA).

B. Chitosan 500 mg/kg tablets (Degree of De-acetylation (93%) and sodium Tri-PolyPhosphate (TPP) were purchased from Sigma Aldrich. Phosphate buffer saline (PBS) and acetic acid were obtained from Sigma-Aldrich, USA.

Study Design:

- Study type: an experimental randomized controlled study.

- Mice were grouped into five main groups; A, B, C and D, as the followings:

(A) A negative Control Group (G1)

(B) A negative control group, which was divided into three sub-groups:

- **Subgroup I (G2):** Received with Praziquantel in a dose of 500 mg/kg orally in two consecutive days (Gonnert and Andrews, 1977).
- **Subgroup II (G3):** Received with Chitosan solution in a dose of 500 mg/kg orally (Schipper *et al* 1999) in two consecutive days.
- **Subgroup III (G4):** Received with PZQ 500 mg/kg and Chitosan 500 mg/kg orally once.

(C) A positive Control Group, which was divided into one subgroup;

- **Subgroup IV (G5):** infected untreated mice.

(D) A Group Harboring the Immature Stages Received Chitosan±Praziquantel Treatments 3 Weeks Post-Infection, And Divided Into Three Subgroups:

- **Subgroup V (G6):** Infected and treated with PZQ alone in a dose of 500 mg/kg in two consecutive days.
- **Subgroup VI (G7):** Infected and treated with Chitosan alone in a dose of 500 mg/kg in two consecutive days.
- **Subgroup VII (G8):** Infected and treated by PZQ 500 mg/kg loaded on Chitosan 500 mg/kg orally once.

(E) A Group Harboring the Mature Stages Received Chitosan ± Praziquantel Treatments after 6 Weeks from Infection, Which Was Divided Into Three Sub-Groups:

- **Subgroup VIII (G9):** Infected and treated by PZQ alone in a dose of 500 mg/kg orally in two consecutive days.
- **Subgroup IX (G10):** Infected and treated by Chitosan alone in a dose of 500 mg/kg orally in two consecutive days.

- **Subgroup X (G11):** Infected and treated by PZQ 500 mg\ kg loaded Schistosomiasis 500 mg\ kg orally once.

Parasitological Parameters:

A. Worm Burden: Infected animals were perfused to recover hepatic and Portomesenteric worms for subsequent counting (Smithers and Terry, 1965).

B. Oogram Pattern: by (Pellegrino et al., 1962).

C. Tissue Egg Load: The number of eggs per gram tissue (liver and intestine) was studied according to the procedure described by (Cheever, 1970).

Statistical analysis

The collected data will be tabulated and analyzed using IBM's personal computer

using SPSS 16 microstate software package. ANOVA (analysis of variance) was used as the test of significance. P-value was considered significant if it was <0.05 (Field, 2000). T-test was used as the multiple comparison tests between all groups and the infected one to determine which pair was significantly different (Abdi and Sidak, 2007).

RESULTS AND DISCUSSION

1) Worm Burden:

In PZQ treated group 6 weeks PI (G 9), in a Chitosan loaded with PZQ treated group 6 weeks post-infection (G 11) and 3 weeks post-infection (G 8) the results were showed highly significant from those recorded in infected control mice ($P<0.001$).

Table (1): Worm burden in *Schistosoma mansoni* infected mice treated with chitosan±praziquantel 3 and 6 weeks post-infection and scarified after 8 weeks from infection, which expressed as mean number (M) \pm standered error (S.E.).

Animal groups infected	Mean worm burden \pm S.E. (Hepatic+portomesentric)			Total worm burden	Worm % reduction
	Male	Female	Couples		
(G5) positive control.	2.470 \pm 0.633	6.633 \pm 1.713	4.833 \pm 0.418	13.936 \pm 0.793	
(G6) PZQ 3 weeks PI.	2.001 \pm 0.443	4.333 \pm 0.700	0.250 \pm 0.22***	6.584 \pm 1.403*	52.76
(G7) chitosan 3 weeks PI.	0.00 \pm 0.00***	3.250 \pm 0.521*	3.772 \pm 0.462	7.022 \pm 1.010*	49.61
(G8) PZQ+ chitosan 3 weeks PI.	0.00 \pm 0.00***	2.671 \pm 0.375**	0.503 \pm 0.399***	3.174 \pm 0.698***	77.22
(G9) PZQ 6 weeks PI.	0.604 \pm 0.438***	0.600 \pm 0.508***	0.00 \pm 0.00***	1.204 \pm 0.933***	91.36
(G10) chitosan 6 weeks PI.	2.002 \pm 0.443	4.752 \pm 0.567	0.400 \pm 0.739***	7.154 \pm 0.786	48.67
(G11) PZQ+ chitosan 6 weeks PI.	0.00 \pm 0.00***	0.401 \pm 0.529***	0.00 \pm 0.00***	0.401 \pm 0.970***	97.12

-*** Highly significant difference from the infected untreated group ($P<0.001$)

-** Moderately significant difference from the infected untreated group ($P<0.01$)

-*Significantly relative to the infected untreated group ($P<0.05$)

2) Oogram Pattern:

In (G8,G9,G11) showed a highly significant difference in the dead ova mean number reached 77.397 \pm 5.163, 97.20 \pm 7.998

and 97.20 \pm 7.998 respectively from those recorded in negative control mice 18.30 \pm 4.020 ($P<0.001$).

Table (2): Oogram pattern in *Schistosomamansoni* infected mice treated with chitosan±praziquantel 3 and 6 weeks post-infection and sacrificed after 8 weeks from infection.

Animal groups infected	Mean number of immature ova±S.E	Mean number of mature ova±S.E	Mean number of deadova±S.E
(G5) positive control.	54.50±4.647	27.20±1.840	18.30±4.020
(G6) PZQ 3 weeks PI.	24.40±4.862*	21.00±1.942	54.60±4.208**
(G7) chitosan 3 weeks PI.	29.00±4.832	23.40±2.028	47.60±3.590*
(G8) PZQ+ chitosan 3 weeks PI.	16.833±4.043**	5.77±1.536***	77.397±5.163***
(G9) PZQ 6 weeks PI.	0.8±0.536***	2.00±1.961***	97.20±7.998***
(G10) chitosan 6 weeks PI.	33.2±4.018	21.00±1.815	45.80±2.343*
(G11) PZQ+ chitosan 6 weeks PI.	0.20±0.054***	0.20±0.109***	97.20±7.998***

-Values are expressed as mean ± S.E.

-The count of each stage represents its existence in a total of 100 ova.

-.*** Highly significant difference from infected untreated group (P<0.001)

-.** Moderately significant difference from the infected untreated group(P<0.01)

-.*Significantly relative to the infected untreated group (P< 0.05)

3) Biochemical Studies:

In ALT results ,collectively (G6, G8, G9, G11) showed a non-significant reduction where the mean number reached 51.50 ± 7.477U\L, 55.50 ± 7.880U\L, 59.00 ± 8.250 U\L and 43.00 ± 6.710U\L respectively compared with negative control mice (G1)(P>0.05). Collectively in AST results (G

5, G 6, G 7, G 8, G 9, G 10, G 11) have a highly significant difference in the mean number 443.00 ± 64.000 U\L, 391.90 ± 56.777 U\L, 387.50 ± 56.000U\L, 349.50 ± 50.333U\L, 214.43 ± 30.293 U\L, 498.00 ± 72.333 U\L and 211.50 ± 29.860 U\L in its comparison with negative control group (G 1) (P<0.001).

Table (3): The effect of chitosan±praziquantel 3 and 6 weeks post-infection on the liver functions in *Schistosoma mansoni* infected mice scarified after 8 weeks from infection.

Animals groups	ALT	AST
(G1) negative control.	43.52 ± 6.837	23.85± 6.687
(G 2) negative control+PZQ.	31.29± 5.913	37.86± 5.897
(G 3) negative control+chitosan.	52.50± 7.577	35.850 ± 4.693
(G 4) negative control+PZQ +chitosan.	58.00± 8.143	30.450± 4.100
(G 5)Positive control.	62.50± 8.633*	443.00±64.000***
(G 6)positive control+PZQ 3 weeks PI.	51.50± 7.477	391.90 ±56.777***
(G 7)positive control+chitosan 3 weeks PI.	70.50± 9.667**	387.50 ± 56.000 ***
(G 8)positive control+PZQ+chitosan 3 weeks PI.	55.50± 7.880	349.50± 50.333***
(G 9)positive control+PZQ 6 weeks PI.	59.00± 8.250	214.43± 30.293***
(G 10)positive control+chitosan 6 weeks PI.	87.00 ±11.617***	498.00± 72.333***
(G 11)positive control+PZQ+chitosan 6 weeks PI.	43.00± 6.710	211.50± 29.860***

-.*** Highly significant difference from the negative control group (P<0.001)

-.** Moderately significant difference from the negative control group (P<0.01)

-.*Significantly relative to the negative control group (P< 0.05)

Schistosomiasis is an important parasitic disease caused by trematode worms of the genus *Schistosoma*. Schistosomiasis control strategies are predominantly based on the treatment of infected individuals with effective drugs.

Recently, nanotechnology holds promise for medication and nutrition, because of materials at the nanometer dimension exhibit novel properties different from those of both isolated atoms and bulk material. Developed nanoparticles have great

potential to overcome the limitations associated with products currently available in the market for the treatment of schistosomiasis. Also, the use of nanotechnology can provide a novel diagnostic assay for Schistosomiasis (Mohamed *et al.*, 2016).

Worm burden reduction is one of the most important assessments in drug efficacy (He XY *et al.*, 1992). Concerning the PZQ effect on immature stage (juvenile stage) there was a mild significant reduction effect, it reached 52.76% which shows a deficiency in its activity spectrum. The low efficacy observed in immature stage when using PZQ as a treatment explained the treatment failure in a highly endemic area of schistosomiasis (Shu-hua *et al.*, 1985; Botros *et al.*, 2005 and Doenhoff *et al.*, 2008). The present study showed that the efficacy of chitosan as a nanoparticle loaded with PZQ in juvenile stage has a highly significant reduction reached 77.22%, which means using nanoparticles chitosan in PZQ delivery has a high Percentage in schistosomiasis treatment even in immature stage. Concerning with PZQ treatment on mature stage found that, the reduction in the worm burden reached 91.36%, it means it still has high efficacy in this stage of the disease and that explained why PZQ has a wide range in its distribution (El-Bassiouni *et al.*, 2016). On the other side the effect of chitosan on mature stage reached 48.67%, it showed low efficacy in this stage compared with its effect on juvenile stage, which means the complications of the disease were higher than its effect. The effect of chitosan loaded with PZQ after 6 weeks from infection (mature stage) reached 97.12% in worm burden reduction, this result was the highest percentage observes in the present study. This result refers to, chitosan success in delivering the PZQ to its target directly protecting the drug from any external or internal factors can affect the cure.

The chemotherapy is considered effective against *S. mansoni* when the Oogram pattern shows increase in the dead ova or disappearance of 50% or more from

mature stage (Pellegrino *et al.*, 1962). Using Chitosan loaded with PZQ as nanoparticles showed increasing the dead ova reached 99.6% and approximately absence of mature and immature ova in the adult stage of *S. mansoni*. While using PZQ chemotherapy orally alone, its effect on mature stage reached 97.2% it approximately as the study reported by (Rabia *et al.*, 2010) where PZQ treatment reached 100% dead ova; but it can't be ignored that mass treatment has been proven to be insufficient to stop disease transmission, prevent re-infection, or reduce parasite-induced illness (King, 2009 and Matthews, 2011).

Determination of enzymes levels, such as ALT and AST is largely used during the assessment of liver damage by schistosomal infection (Al-sayed *et al.*, 2014 and Aly and Mantawy, 2013). Due to membrane damage (necrosis) the liver releases the enzymes into circulation so they can be measured in the serum (Fahmy *et al.*, 2014). The increment of such enzymes in serum may be due to destruction in hepatocytes by the action of parasite egg toxins which lead to their release into the circulation (Kadry *et al.*, 2013 and Mahmoud and Elbessoumy, 2013). Membrane damage seems to be prim culprit for the marked increase in the serum marker enzymes such as ALT, AST following the infection of *Schistosoma* (Naik *et al.*, 2011). In this study, the comparison between all groups with the negative control mice in, ALT level showed a high elevation in mice treated with Chitosan as a treatment for schistosomiasis in both immature and mature stages. The observed elevation in ALT reflects either acute active or chronic liver damage (Naik and Panda, 2007), this could be associated with mal-absorption due to damaged intestinal mucosa resulting from the extrusion of large numbers of eggs, or could be due to decreased synthesis, which may result from parasitic injury to hepatic cells (Oliveira *et al.*, 2004 and Fahmy *et al.*, 2014).

On the other hand, the effect of PZQ on both immature and mature stages showed no

elevation in ALT level. PZQ therapy has been associated with an elevation in serum ALT in up 27% of patients (Zimmerman, 1999)

In Chitosan loaded PZQ as nanoparticles found that, there was no elevation in ALT level which means it may not lead to cell membrane damage and convey the treatment directly to its target organ.

Despite extensive research into the biomedical and pharmaceutical applications of nanoparticles, and the liver being the main detoxifying organ in the human body, there are limited studies that delineate the hepatotoxicity of nanoparticles (Jing *et al.*, 2010).

In the current study, AST level has a high elevation in all mice infected and treated with different treatments. PZQ increase AST level in serum (El-Lakkany, 2011) but still mice treated with Chitosan loaded PZQ have less chance in AST elevation from those recorded in negative control mice.

REFERENCES

- Abdi H. Bonferroni and Sidak Z., 2007. Corrections for multiple comparisons. In: Salkind NJ, editor. Encyclopedia of measurement and statistics. Thousand Oaks, CA: SageOaks, California, USA: pp. 103–107.
- Al-Sayed E.; Hamid H.A. and Abu El Einin H.M., 2014. Molluscicidal and antischistosomal activities of methanol extracts and isolated compounds from *Eucalyptus globulus* and *Melaleuca styphelioides*. Pharm. Biol., 52(6):698–705.
- Aly H.F. and Mantawy M.M., 2013. The efficiency of ginger (*Zingbar officinale*) against *Schistosoma mansoni* infection during host-parasite association. Parasitol. Int., 62 (4):380–389.
- Bell L. N., 2001. Handbook of Nutraceuticals and Functional Foods. New York, U.S.A, 501-516.
- Botros S. ; LiviaPica-Mattoccia; William S.; El-Lakkani N. and Cioli D., 2005. Effect of praziquantel on the immature stages of *Schistosoma haematobium*. Int. J. parasitol., 35 (13): 1453-1457.
- Cheever A. W., 1970. Relative resistance of the eggs of human schistosomes to digestion in potassium hydroxide. Bull. World Health Organ. 43(4): 601–603.
- Cioli, 2000. Praziquantel: is their real resistance and are their alternatives?. Curr. Opin. Infect. Dis., 13:659–663.
- Danso-Appiah A.; Olliaro P. L.; Donegan S.; Sinclair D. and Utzinger J., 2013. Drugs for treating *Schistosoma mansoni* infection. The Cochrane Database of Systematic Reviews. 2 (2): CD000528.
- Doenhoff Michael J.; Cioli Donato and Utzinger Jürg., 2008. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Cur. Opin. Infect. Dis., 21 (6) : 659–667.
- El-Bassiouni E.A. ; Helmy M. H. ; Saad E.I. ; El-Nabi Kamel ; E. Abdel-Meguid and Hussein H.S.E., 2016. Modulation of the antioxidant defense in different developmental stages of *Schistosoma mansoni* by praziquantel and artemether. British J. Biomed. Sci., 64(4): 168-174.
- El-Lakkany N.M.; Seif El-Din S.H. and Ebeid, F., 2011. The use of pentoxifylline as adjuvant therapy with praziquantel downregulates profibrogenic cytokines, collagen deposition and oxidative stress in experimental schistosomiasis *mansoni*. Exp. Parasitol., 129 (2):152-157.
- Fahmy S.R. ; Rabia I. and Mansour E.M., 2014. The potential role of mefloquine against *Schistosoma mansoni* infection by prohibition of hepatic oxidative stress in mice. JOB AZ, 67:40–47.
- Field, A. 2000. Discovering Statistics Using SPSS for Windows. SAGE publications, Thousand Oaks – New Delhi, London.
- Gonnert R. and Andrews P. Z. F. Parasitenkunde, 1977. Praziquantel, a new broad-spectrum antischistosomal agent Praziquantel: a new broad-

- spectrum antischistosomal agent. *Parasitol. Res.*, 52: 129-150.
- He XY; Hu QY and Yu FQ. 1992. The sensitivity of different isolates of *Schistosoma japonicum* from China to praziquantel. *Southeast Asian J. Trop. Med. Health*, 23: 261–3.
- Hotez J.; Fenwick A.; Savioli L.; Molyneux D.H., 2009. Rescuing the bottom billion through control of neglected tropical diseases. *Lancet*, 373:1570–5.
- Islam N. and Ferro V., 2016. Recent advances in chitosan-based in vector-transmitted parasites. *Science*, 331: 1149–1153.
- Jing WenLoh ; George Yeoh ; Martin Saunders and Lee-Yong Lim, 2010. Uptake and cytotoxicity of chitosan nanoparticles in human liver cells. *Elsevier*, 249(2):148-157.
- Kadry S.M. ; Mohamed A.M.; Farrag E.M.; Dalia B. and Fayed D.B., 2013. Influence of some micronutrients and *Citharexylum quadrangular* extract against liver fibrosis in *Schistosoma mansoni* infected mice. *Afr. J. Pharm. Pharmacol.*, 7 (38): 2628–2638.
- King C. H., 2009. Global health: toward the elimination of schistosomiasis. *New England J. Med.*, 360(2) pp: 106–109.
- Kwon Y. J.; James E. ; Shastri ; N. and Fréchet J. M. 2005. In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on PH-responsive microparticles. *Proc. Natl. Acad. Sci. U.S.A.*, 102:18264–18268.
- Lammie P. J.; Fenwick A. and Utzinger J., 2006. A blueprint for success: Integration of neglected tropical disease control programmes. *Trends Parasitol.*, 22: 313–21.
- Mahmoud E.A. and Elbessoumy A.A., 2013. Effect of curcumin on hematological, biochemical and antioxidants parameters in *Schistosoma mansoni* infected mice. *Int. J. Sci.*, 2: 1–14.
- Matthews K. R., 2011. Controlling and coordinating development in vector transmitted parasites. *Science*, 331(6021):1149-1153.
- Mohamed AH, Osman GY, Zowail ME, El-Esawy HM. 2016. Effect of *Lactobacillus sporogenes* (probiotic) on certain parasitological and molecular aspects in *Schistosoma mansoni* infected mice. *J Parasit Dis.* 40(3):823-32
- Naik S.R. and Panda V.S., 2007. Antioxidant and hepatoprotective effects of Ginkgo biloba phytosomes in carbon tetrachloride-induced liver injury in rodents. *Liver Int.*, 27:393-399.
- Naik S.R.; Thakare V.N. and Patil S.R., 2011. Protective effect of curcumin on experimentally induced inflammation, hepatotoxicity and cardiotoxicity in rats: Evidence of its antioxidant property. *Exp. Toxicol. Pathol.*, 63: 419–431.
- Oliveira C. R.; C'ntia M.F.; Silva M. R.; Borges O. M.; P'ego A. P.; and Goes A. M., 2012. Oral Vaccination Based on DNA-Chitosan Nanoparticles against *Schistosoma mansoni* Infection. *Int. J. Sci. World*, 11.
- Pellegrino J. ; Oliveira C.A. ; Faria J. and Cunha A.S., 1962. New approach to screening of drugs in experimental *Schistosoma mansoni* in mice. *Am. J. Trop. Med. Hyg.*, 11: 201-215.
- Piper P. Karen; Richard F. Mmottand Diane J. McLAREN, 1990. *Schistosoma mansoni*: Histological analysis of the synergistic interaction between vaccine immunity and praziquantel therapy in the lungs of mice. *Parasite Immunol.*, 12 : 367–387.
- Rabia I.; Nagy F.; Aly E.; Mohamed A.; EL-Assal F. and El- Amir A., 2010. Effect of treatment with antifibrotic drugs in combination with Pzq in immunized *Schistosoma mansoni* infected murine model. *J. Am. Sci.*, 6 (5):208–216.
- Reddy S. T. ; Van Der Vlies A. J. ; Simeoni E. ; Angeli V. ; Randolph G. J. and O'neil, C. P., et al. 2007. Exploiting

- lymphatic transport and complement activation in nanoparticle vaccines. *Nat. Biotechnol.*, 25:1159–1164.
- Schipper N.G.; Vårum K.M.; Stenberg P., et al., 1999. Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement. *Eur. J. Pharm. Sci.* 1999; 8:335–43.
- Shrestha N. ; Shahbazi M. A. ; Araújo F. ; Zhang H. ; Mäkilä E. M. ; Kauppila J. and et al., 2014. Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers. *Biomaterials* 35:7172–7179.
- Shu-hua Xiao ; Brian A. Catto and Leslie T. Webster, Jr., 1985. Effects of Praziquantel on Different Developmental Stages of *Schistosoma mansoni* in Vitro and in Vivo. *J. Infect. Dis.*, 151 (6): 1130–1137.
- Smithers S.R. and Terry R.J.P.M., 1965. Infection of laboratory hosts with cercaria of *Schistosoma mansoni* and the recovery of adult worms. *Parasitology*, 55: 695–700.
- Steinmann P.; Keiser J. ; Bos R. ; Tanner M. and Utzinger J., 2006. Schistosomiasis and water resources development: Systematic review, meta-analysis, and estimates of people at risk. *Lancet Infect. Dis.*, 6: 411–425.
- Thétiot-Laurent A.L Sophie; Dr. Jérôme Boissier ; Dr. Anne Robert ; Prof. Dr. Bernard Meunier, 2013. Schistosomiasis Chemotherapy. *J. chem. Soc.*, 52(31):7936–7956
- Zimmerman H.J., 1999. Antihelminthics. Hepatic injury from antimicrobial agents. In, Zimmerman HJ. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott. 626–8.

ARABIC SUMMARY

تأثير جزيئات الشيتوسان متناهية الصغر والمحملة بالبرازيكوانتيل على الفئران المصابة بالبلهارسيا المعوية

نورمان احمد عبده¹, ماهي عبد الفتاح غباشي¹, سهير سيد محمود², علا علي اسماعيل³, احسان احمد حسن²

1- قسم علم الحيوان - كلية العلوم - جامعة قناة السويس

2- قسم الطفيليات - معهد تيودور بلهارس للأبحاث

3- كلية الطب - جامعة قناة السويس

بالرغم ان البلهارسيا مرض منتشر عالميا , حيث يؤثر في اكثر من 200 مليون شخص حول العالم و لكنه يعتمد كليا و فقط علي علاج وحيد يؤخذ عبر الفم و هو البرازيكوانتيل. منذ تطور البرازيكوانتيل عام 1970 فقد احتل بديلا عن جميع العلاجات الاخرى الخاصة بمرض البلهارسيا و ذلك لعدة اسباب منها: كفاءته العالية, قلة اثاره الجانبية بالاضافة الي سرعة المناسبات جدا و لكن هناك عدة عوامل اخرى تؤثر بشكل او بآخر علي كفاءته منها عوامل داخلية مثل (درجة الحموضة و الانزيمات) و خارجية مثل (درجة الحرارة و الرطوبة). فاصبح من الهام تطور البرازيكوانتيل للتحكم اكثر بانتشار ظاهرة البلهارسيا, و ذلك مع ظهور جزيئات الشيتوسان النانوية و ذلك لقدرنها الفائقة في الثبات و خصائصها في الاستجابة المناعية. فهذا البحث هدفة هو معرفة تأثير جزيئات الشيتوسان النانوية و المحمل بالبرازيكوانتيل كموصل للعلاج علي العوامل الطفيلية مثل (عدد الديدان, عدد البويضات الميتة , عدد البويضات في انسجة الكبد و الامعاء الدقيقة) و العوامل البيوكيميائية.

و جاءت النتائج بان جزيئات الشيتوسان النانوية و المحملة بالبرازيكوانتيل كان لها تأثير كبير حيث وصل نسبة الانخفاض في عدد الديدان الي 97.12% و وصل عدد البويضات الميتة الي 99.6% و زادت نسبة الانخفاض في عدد البويضات بانسجة الكبد الي 96.17% و انسجة الامعاء الدقيقة الي 97.39% مع تحسن في العوامل البيوكيميائية.